Most cited papers from Hospital Muñiz

Hospital Muñiz

What are the most cited papers from Hospital Muñiz?

The most cited paper from Hospital Muñiz is "WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update" (Dennis Falzon et al., 2011), with 1,106 citations. Next come "Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis" (648) and "Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis" (554).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 90 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Dennis Falzon et al. · European Respiratory Journal Open access	2 Aug 2011	1,106
2	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis Nafees Ahmad et al. · The Lancet ReviewOpen access108 authors	Sep 2018	648
3	Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis Carlos Jose Pirola, Tomas Fernández Gianotti, Gustavo Osvaldo Castaño et al. · Gut Open access	27 Jun 2014	554
4	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients Shama Desai Ahuja et al. · PLoS Medicine ReviewOpen access	28 Aug 2012	542
5	Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease Carlos Jose Pirola, Tomas Fernández Gianotti, Adriana Laura Burgueño et al. · Gut Open access	9 Aug 2012	362
6	Epigenetic Regulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease Silvia C. Sookoian, María Soledad Rosselli, Carolina Gemma et al. · Hepatology Open access	22 Aug 2010	329
7	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study Sergey E. Borisov et al. · European Respiratory Journal Open access	May 2017	310
8	Person-to-Person Transmission of Andes Virus Valeria P. Martínez, Carla Bellomo, Jorge San Juan et al. · Emerging infectious diseases Open access	Dec 2005	308
9	Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection David A. Cooper et al. · The Journal of Infectious Diseases	19 Feb 2010	267
10	Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis Javier O. Jurado, Ivana B. Alvarez, Virginia Pasquinelli et al. · The Journal of Immunology Open access	Jul 2008	256
11	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis Giovanni Battista Migliori, Giovanni Sotgiu, Neel R. Gandhi et al. · European Respiratory Journal ReviewOpen access	11 Oct 2012	253
12	Activity of posaconazole in the treatment of central nervous system fungal infections Punnee Pitisuttithum, Ricardo Negroni, John R. Graybill et al. · Journal of Antimicrobial Chemotherapy Open access	31 Aug 2005	250
13	Nocardiosis: a review Marcelo Corti, María E. Villafañe Fioti · International Journal of Infectious Diseases Open access	Dec 2003	219
14	Pediatric and adult forms of type I autoimmune hepatitis in argentina: Evidence for differential genetic predisposition Marcelo Jorge Pando, J. Larriba, Gabriela Cristina Fernández et al. · Hepatology Open access	Dec 1999	219
15	Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections ISSAM I. RAAD, John R. Graybill, A. B. Bustamante et al. · Clinical Infectious Diseases	18 May 2006	217
16	The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? – Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI) Cristián Biscayart, Patricia Angeleri, Susana Cristina Lloveras et al. · Travel Medicine and Infectious Disease Open access	2020	198
17	Clinical standards for the assessment, management and rehabilitation of post-TB lung disease Giovanni Battista Migliori et al. · The International Journal of Tuberculosis and Lung Disease Open access	Oct 2021	192
18	Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial Mark Sulkowski, Stanislas Pol, Josep Mallolas et al. · The Lancet Infectious Diseases	12 Jun 2013	183
19	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report Sergey E. Borisov et al. · European Respiratory Journal Open access	10 Oct 2019	181
20	Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study Stefano Aliberti et al. · The Lancet Infectious Diseases Open access276 authors	6 Sep 2016	180
21	Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study Kristina M Angelo et al. · The Lancet Infectious Diseases Open access	7 Oct 2022	175
22	Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study Elisa Estenssoro et al. · The Lancet Respiratory Medicine Open access150 authors	2 Jul 2021	175
23	Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals Silvia C. Sookoian, Gustavo Osvaldo Castaño, Carlos Jose Pirola · Gut ReviewOpen access	11 Sep 2013	165
24	Extended-Spectrum β-Lactamases in Enterobacteriaceae in Buenos Aires, Argentina, Public Hospitals Mirta Quinteros, Marcela A. Radice, Noella Gardella et al. · Antimicrobial Agents and Chemotherapy Open access	22 Aug 2003	164
25	IL-17 and IFN-γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease Javier O. Jurado, Virginia Pasquinelli, Ivana B. Alvarez et al. · Journal of Leukocyte Biology Open access	14 Mar 2012	164
26	Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992–2007 Ezequiel Córdova, Analía Boschi, Juan Ambrosioni et al. · International Journal of Infectious Diseases Open access	13 Mar 2008	163
27	Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans Digna Rosa Velez, Christian Morberg Wejse, Martín E. Stryjewski et al. · Human Genetics Open access	21 Sep 2009	162
28	Neutrophil Extracellular Traps in Sepsis Gabriela Camicia, Roberto Gabriel Pozner, Gabriela Fernanda De Larrañaga · Shock Open access	9 Jul 2014	160
29	Posaconazole treatment of refractory eumycetoma and chromoblastomycosis Ricardo Negroni, Ángela María Tobón, Beatriz Bustamante et al. · Revista do Instituto de Medicina Tropical de São Paulo Open access	Dec 2005	157
30	Mpox in people with past infection or a complete vaccination course: a global case series Aniruddha Hazra et al. · The Lancet Infectious Diseases Open access	4 Sep 2023	149
31	Salvage treatment of histoplasmosis with posaconazole Ángela Restrepo, Ángela María Tobón, Benjamin Clark et al. · Journal of Infection	8 Jul 2006	149
32	Tuberculosis is associated with expansion of a motile, permissive and immunomodulatory CD16+ monocyte population via the IL-10/STAT3 axis Claire Lastrucci, Alan Bénard, Luciana Balboa et al. · Cell Research Open access	20 Oct 2015	149
33	Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease Carlos Jose Pirola, Martin E. Garaycoechea, Diego Flichman et al. · Journal of Lipid Research Open access	15 Oct 2018	142
34	Point of care diagnostics for tuberculosis Alberto L. García‐Basteiro, Andrew R. DiNardo, Belén Saavedra et al. · Pulmonology Open access	14 Feb 2018	132
35	Recombinant Tissue Factor Pathway Inhibitor in Severe Community-acquired Pneumonia: A Randomized Trial Richard G. Wunderink, Pierre-François Laterre, Bruno François et al. · American Journal of Respiratory and Critical Care Medicine	4 Feb 2011	128
36	Tuberculosis Exacerbates HIV-1 Infection through IL-10/STAT3-Dependent Tunneling Nanotube Formation in Macrophages Shanti Souriant et al. · Cell Reports Open access	Mar 2019	125
37	Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study Cristina Mussini et al. · Clinical Infectious Diseases Open access	5 Feb 2004	124
38	Rickettsia parkeri Rickettsiosis, Argentina Yamila Romer · Emerging infectious diseases Open access	Jul 2011	123
39	Prevalence of hepatitis viruses in an anti‐human immunodeficiency virus‐positive population from Argentina. Amulticentre study Hugo Alberto Fainboim, Juan C FalcÃ n GonzÃ¡lez, E Fassio et al. · Journal of Viral Hepatitis	1999	123
40	Chronic active autoimmune hepatitis in children Leonardo Fainboim, Yanina C. Marcos, Marcelo Jorge Pando et al. · Human Immunology	Oct 1994	122
41	Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis Melisa Dirchwolf · World Journal of Hepatology Open access	2015	121
42	Role Played by the Programmed Death‐1–Programmed Death Ligand Pathway during Innate Immunity againstMycobacterium tuberculosis Ivana B. Alvarez, Virginia Pasquinelli, Javier O. Jurado et al. · The Journal of Infectious Diseases Open access	9 Jul 2010	121
43	Liver injury after SARS‐CoV‐2 vaccination: Features of immune‐mediated hepatitis, role of corticosteroid therapy and outcome Cumali Efe et al. · Hepatology Open access	14 May 2022	118
44	Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity Melisa Dirchwolf, Ariel Podhorzer, Mónica Marino et al. · Cytokine Open access	24 Oct 2015	118
45	Mycoses associated with AIDS in the Third World Sílvio Alencar Marques, Ana María Robles, Anna Maria Tortorano et al. · Medical Mycology	2000	118
46	Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Trial Ulrik Bak Dragsted, Jan Gerstoft, Court Pedersen et al. · The Journal of Infectious Diseases Open access	22 Aug 2003	118
47	Prevalence of extended-spectrum β-lactamases in South America María Virginia Villegas, Juan Nicolás Kattán, Mirta Quinteros et al. · Clinical Microbiology and Infection Open access	2008	113
48	Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin Luis J. Gonzalez-Montaner et al. · Tubercle and Lung Disease	Oct 1994	113
49	Oral Treatment of Paracoccidioidomycosis and Histoplasmosis with Itraconazole in Humans Ricardo Negroni, Omar J. Palmieri, F. Koren et al. · Clinical Infectious Diseases	1987	109
50	Correlation between cortisol level and serotonin uptake in patients with chronic stress and depression Gustavo Eduardo Tafet, V. P. IDOYAGA-VARGAS, Denise P. Abulafia et al. · Cognitive Affective & Behavioral Neuroscience Open access	Dec 2001	107

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.